By Adriano Marchese
Eupraxia Pharmaceuticals has appointed Alex Rothwell to return as its next chief financial officer, effective immediately.
Rothwell brings to the clinical-stage biotechnology company more than 25 years of experience as a business leader and as a senior executive in the Canadian capital markets and investment banking, Eupraxia said Tuesday.
He was Eupraxia's CFO from 2018 to 2021.
Most recently, Rothwell has been a senior advisor to Fort Capital Partners, a Canadian boutique investment bank.
Bruce Cousins, the company's outgoing CFO, is set to retire but will remain as a consultant in the near-term to ensure an orderly transition of responsibilities.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 18, 2025 07:16 ET (12:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。